Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company whose news flow centers on its portfolio of FDA-approved brands and its clinical development programs. The company focuses on hospital acute care, gastroenterology, and oncology markets, and its announcements often highlight product milestones, commercialization agreements, and study results that affect how its medicines are used in practice.
Recent news has covered developments for Caldolor (ibuprofen) injection, including a permanent CMS J-code associated with a reimbursement price that supports its use as a non-opioid option for managing pain and fever. Cumberland has also reported regulatory approval of its ibuprofen injection product in Mexico through a partnership with PiSA Farmaceutica, reflecting the company’s efforts to expand access to its hospital acute care therapies internationally.
Another recurring theme in CPIX news is the expansion of Vibativ (telavancin) injection. Press releases describe new supply arrangements and group purchasing agreements with organizations such as Vizient and Premier in the United States, as well as the launch of Vibativ in Saudi Arabia through Tabuk Pharmaceutical Manufacturing Company. These updates explain how hospitals and providers can access Vibativ in different configurations and markets.
Cumberland’s news also highlights its ifetroban Phase II clinical programs in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis, including presentations of trial data and regulatory interactions. In addition, investors can follow revenue updates and quarterly financial results, which break down net revenues by product such as Kristalose, Sancuso, Vibativ, and Caldolor.
For readers tracking CPIX, the news stream provides insight into product-level performance, international partnerships, reimbursement developments, and the progress of late-stage clinical studies. Bookmarking this page can help investors, clinicians, and other stakeholders follow key events affecting Cumberland’s commercial portfolio and pipeline.
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q1 2026 net revenues of $9.1 million and a net loss of $3.3 million. The company announced a $100 million strategic transaction to sell its FDA-approved branded U.S. portfolio to Apotex, while retaining development programs and majority ownership of Cumberland Emerging Technologies.
At March 31, 2026, total assets were $71.0 million, liabilities $49.7 million, and shareholders' equity $21.6 million. Ifetroban programs hold Fast Track, Orphan Drug, and Rare Pediatric Disease designations.
RedHill (CPIX) reported in vitro data showing its next-generation oral candidate RHB-204 demonstrates MAP killing comparable to RHB-104, achieved in spot and phage assays and using lower doses of two active ingredients. A Phase 2 trial in MAP-positive Crohn's disease patients is planned, with non-dilutive funding sought and multiple regulatory designations and patent protection through 2041.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will release Q1 2026 financial results and provide a company update after market close on May 5, 2026. A conference call is scheduled for May 5 at 4:30 p.m. ET, with registration, live dial‑in, a "Call Me" option, and a one‑year replay.
The company listed its FDA‑approved branded portfolio including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ and Talicia. Cumberland also noted ongoing Phase II programs for ifetroban in systemic sclerosis, Duchenne cardiomyopathy, and idiopathic pulmonary fibrosis.
RedHill Biopharma (Nasdaq: RDHL) reported full-year 2025 results and operational highlights on April 27, 2026, citing strategic transactions, commercial progress for Talicia and focused R&D activity. Key items include a $4.0M Cumberland investment into Talicia Holdings, Talicia U.S. net revenues of ~$8.9M, ex-U.S. revenues of ~$1.9M, a RHB-102 licensing deal worth up to $60M in milestones, a final $10.5M New York Supreme Court judgment in RedHill's favor, year-end cash of $4.1M and positive equity of $4.3M.
Cumberland Pharmaceuticals (Nasdaq: CPIX) agreed to sell its U.S. branded pharmaceuticals business to an affiliate of Apotex for $100 million in cash, subject to shareholder approval. Cumberland will retain its development pipeline, majority ownership of Cumberland Emerging Technologies, and focus on advancing ifetroban clinical programs.
The company reported Phase II breakthrough results in DMD cardiomyopathy, ongoing FDA interactions, and active Phase II studies in systemic sclerosis and idiopathic pulmonary fibrosis.
RedHill (Nasdaq: RDHL) presented independent preclinical data at AACR 2026 showing that opaganib may enhance chemotherapy efficacy in high‑risk neuroblastoma and augment STING‑mediated anti‑tumor immunity in triple‑negative breast cancer (TNBC).
Penn State and Apogee data indicate opaganib destabilized n‑Myc and increased ceramide‑driven apoptosis with OXDOX; University of Kansas data show opaganib plus low‑dose diABZI potentiated STING effects in TNBC. Opaganib holds FDA Orphan and Rare Pediatric Disease designations for neuroblastoma.
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced FDA approval on April 16, 2026 for an expanded indication of Caldolor (ibuprofen) Injection to include management of postoperative pain in adults and pediatric patients ages 3 months and older.
The company also launched a redesigned website for healthcare professionals featuring perioperative resources, dosing, safety, and J-Code reimbursement support.
Cumberland Pharmaceuticals (Nasdaq: CPIX) launched an updated Sancuso website on March 17, 2026, offering educational resources for chemotherapy-induced nausea and vomiting (CINV).
The site highlights Sancuso as the only prescription granisetron transdermal patch approved by the FDA to prevent CINV for up to five days, and includes clinical data, HCP tools, patient education, and prescribing information.
H. pylori infections market (CPIX) is projected to expand from a USD 270 million market in 2025 at a 9.4% CAGR through 2036 across the 6MM. US holds ~85% of 2025 revenue and ~57 million diagnosed prevalent cases; emerging therapies such as rifasutenizol, linaprazan glurate, and tegoprazan are expected to reshape treatment paradigms with reported Phase III eradication rates >90% for some candidates.
Challenges include a limited pipeline, geographic regulatory gaps, rising antibiotic resistance, and adherence issues with high pill burdens.
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q4 2025 combined net revenues of $13.7M, up 31% year-over-year, and full-year 2025 net revenues of $44.5M, up 18% versus 2024. The company posted a $2.9M net loss for 2025 and $1.7M adjusted earnings. Total assets were $76.8M and shareholders' equity was $24.9M at year end.
Key developments: international launches/approvals, Talicia co-commercialization, permanent J-code for Caldolor, positive FIGHT DMD Phase II topline results and FDA fast track designation in early 2026.